Member Profile Page




Grynpas, Marc - PhD

University of Toronto Appointment(s): Professor, Department of Laboratory Medicine and Pathobiology

Other Appointment(s): Director, Bone and Mineral Group

Contact Information:

Mount Sinai Hospital
600 University Avenue, Suite 840
Toronto, Ontario, M5G 1X5

Phone: 416-586-4800 Ext: 4464
Fax: 416-586-1554
Email: grynpas@lunenfeld.ca
Websites: http://www.mshri.on.ca/grynpas/default.asp

Diabetes Related Research Activities:

Our research focuses on the effects of diabetes on the skeletal system using pre-clinical models. Examples of our research includes:

1)  Effect of Vanadium Treatment on Bone Loss and Bone Quality in Rat Models of Diabetes. Vanadium compounds have been shown to be effective in experimental diabetes and insulin-resistant hypertension. However, these agents are known to accumulate in bone mineral where vanadate substitutes for phosphate. It is therefore essential to understand the long-term effects on these compounds on bone quality. (Facchini DM, Yuen VG, Battell ML, McNeill JH, Grynpas MD. The effects of vanadium treatment on bone in diabetic and non-diabetic rats. Bone. 2006; 38(3):368-77)

2)  The effect of Rosiglitazone treatment on bone quality in rat models of type 2 diabetes and osteoporosis. Rosiglitazone (RSG) is an insulin-sensitizing drug used to treat patients with Type 2 Diabetes Mellitus (T2DM) to improve glycemic control. The ADOPT clinical trial showed that women taking RSG experienced more fractures. The purpose of our study is to understand the mechanism by which RSG induces limb fracture and alters bone quality in the insulin resistant Zucker Fatty rat.

3)  Comparison of the skeletal effects in the treatment of type2 diabetes with Sitagliptin (a DPP4 inhibitor) or Pioglitazone (a PPRgamma agonist) in mice fed a high fat diet.

View Publications